Cardiac ion channels function in a sequential and interactive manner to drive the beating of cardiomyocytes. QTempo is the only human pre-clinical functional assay that can capture the complexity of that process. The underlying idea is simple: We (1) generate clusters of spontaneously beating cardiomyocytes from human iPS cells, (2) place these beating cardiomyocytes in a well with electrodes to monitor electropotential, and (3) Measure the effect of compounds and drugs on the waveform.
From this simple idea, the QTempo assay allows analysis of the full range of ion channels. QTempo directly measures not only QT interval, but also a range of other cardiac action potential parameters (such as beat rate and the QRS complex). QTempo identifies compounds that affect Na, K and Ca ion channels and reflects their complex interactions.
Uses beating human heart cells: * Identifies beat rate dependent effects * Identifies compounds that change beat rate * Covers all cardiomyocyte ion channels * Screens non-ion channel factors * Faster, cheaper and kinder than using animals The cardiomyocyte clusters used in QTempo generate robust, consistent data over extended periods. This allows a wide variety of drug concentrations to be sequentially tested, increasing confidence in drug safety before further development.
ReproCELL’s QTempo assay is offered in a variety of formats to suit customer requirements. ReproCELL is licensed by iPS Academia (Kyoto, Japan) to use iPS technology in this assay.
In all our tests, including assays of cardiotoxic compounds not correctly identified by the hERG assay, QTempo has generated results in complete agreement with clinical findings.
Two key technologies developed by ReproCELL underlie QTempo. The first is a protocol for the differentiation of cardiomyocytes from both ES and iPS cells. Secondly, ReproCELL has developed novel protein-free media that maintain the cardiomyocytes whilst allowing stable measurement of electropotential.
Common Cell Transformed into Master Heart Cell By genetically reprogramming the most common type of cell in mammalian connective tissue, researchers at the University of Wisconsin—Madison have generated master heart cells — primitive progenitors that form the developing heart.Improving Regenerative Medicine Lab-created stem cells may lack key characteristics, UCLA research finds.Muscles on-a-Chip This study may help explain why stem cell-based therapies have so far shown limited benefits for heart attack patients in clinical trials.3-D Printed Lifelike Liver Tissue for Drug Screening A team led by engineers at the University of California, San Diego has 3D-printed a tissue that closely mimics the human liver's sophisticated structure and function. The new model could be used for patient-specific drug screening and disease modeling. Therapeutic Approach Gives Hope for Multiple Myeloma A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.Cat Stem Cell Therapy Gives Humans Hope By the time Bob the cat came to the UC Davis veterinary hospital, he had used up most of his nine lives. Bile Acid Supports Production of Blood Stem Cells A research group at Lund University has been able to show that bile acid is transferred from the mother to the foetus via the placenta to enable the foetus to produce blood stem cells.New Biomarker to Assess Stem Cells Developed A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). The team's discovery offers a new way to fast-track screening methods used in stem cell research.Tricked-Out Immune Cells Could Attack Cancer New cell-engineering technique may lead to precision immunotherapies.Edited Stem Cells Offer Hope of Precision Therapy for Blindness Findings raise the possibility of treating blinding eye diseases using a patient's own corrected cells as replacement tissue.